Phaedra C. Ghazi

426 total citations
9 papers, 169 citations indexed

About

Phaedra C. Ghazi is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Phaedra C. Ghazi has authored 9 papers receiving a total of 169 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 2 papers in Oncology and 2 papers in Genetics. Recurrent topics in Phaedra C. Ghazi's work include Ubiquitin and proteasome pathways (2 papers), NF-κB Signaling Pathways (2 papers) and PI3K/AKT/mTOR signaling in cancer (2 papers). Phaedra C. Ghazi is often cited by papers focused on Ubiquitin and proteasome pathways (2 papers), NF-κB Signaling Pathways (2 papers) and PI3K/AKT/mTOR signaling in cancer (2 papers). Phaedra C. Ghazi collaborates with scholars based in United States. Phaedra C. Ghazi's co-authors include Martin McMahon, Conan G. Kinsey, Jesse Lyons, Kevin M. Haigis, Douglas A. Lauffenburger, Katherine Baldwin, Vijay Yajnik, Amanda Truong, Alina Starchenko and Alessio Tovaglieri and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and PLoS Biology.

In The Last Decade

Phaedra C. Ghazi

9 papers receiving 169 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Phaedra C. Ghazi United States	8	91	44	33	29	23	9	169
Peter J. Volberding United States	8	94 1.0×	43 1.0×	23 0.7×	53 1.8×	40 1.7×	9	192
Stephen Harper United Kingdom	7	100 1.1×	46 1.0×	15 0.5×	31 1.1×	19 0.8×	12	163
Jun Won Park South Korea	11	129 1.4×	59 1.3×	20 0.6×	40 1.4×	34 1.5×	29	245
Xinjun Zhao China	4	118 1.3×	25 0.6×	19 0.6×	21 0.7×	23 1.0×	11	209
Xiangling Xiao China	9	154 1.7×	81 1.8×	34 1.0×	42 1.4×	46 2.0×	10	264
Baochen Chong China	3	109 1.2×	25 0.6×	18 0.5×	21 0.7×	23 1.0×	4	183
Tonantzin G. Calvo Spain	4	122 1.3×	35 0.8×	78 2.4×	69 2.4×	28 1.2×	5	212
Yik-Lam Cho Singapore	4	99 1.1×	17 0.4×	72 2.2×	18 0.6×	30 1.3×	5	181
Glowi Alasiri Saudi Arabia	9	156 1.7×	38 0.9×	46 1.4×	13 0.4×	35 1.5×	43	274
Mayuyo Mori‐Uchino Japan	8	107 1.2×	56 1.3×	14 0.4×	44 1.5×	39 1.7×	29	227

Countries citing papers authored by Phaedra C. Ghazi

Since Specialization

Citations

This map shows the geographic impact of Phaedra C. Ghazi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phaedra C. Ghazi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phaedra C. Ghazi more than expected).

Fields of papers citing papers by Phaedra C. Ghazi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Phaedra C. Ghazi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Phaedra C. Ghazi. The network helps show where Phaedra C. Ghazi may publish in the future.

Co-authorship network of co-authors of Phaedra C. Ghazi

This figure shows the co-authorship network connecting the top 25 collaborators of Phaedra C. Ghazi. A scholar is included among the top collaborators of Phaedra C. Ghazi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Phaedra C. Ghazi. Phaedra C. Ghazi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Ghazi, Phaedra C., Mark R. Silvis, Yun Zhang, et al.. (2024). Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer. eLife. 13. 5 indexed citations

Ghazi, Phaedra C., Mark R. Silvis, Yun Zhang, et al.. (2024). Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer. eLife. 13. 9 indexed citations

McMahon, Martin, et al.. (2022). Abstract 3600: DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with the KRASG12C inhibitor sotorasib resulting in tumor regression in KRAS mutant NSCLC xenograft models. Cancer Research. 82(12_Supplement). 3600–3600. 8 indexed citations

Truong, Amanda, Jae Hyuk Yoo, John Michael S. Sanchez, et al.. (2020). Chloroquine Sensitizes GNAQ/11 -mutated Melanoma to MEK1/2 Inhibition. Clinical Cancer Research. 26(23). 6374–6386. 38 indexed citations

Vaishnavi, Aria, Conan G. Kinsey, Amanda Truong, et al.. (2020). Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer. Cell Reports. 32(5). 107994–107994. 17 indexed citations

Ghazi, Phaedra C., Alina Starchenko, Myriam Boukhali, et al.. (2019). Substrate-based kinase activity inference identifies MK2 as driver of colitis. Integrative Biology. 11(7). 301–314. 20 indexed citations

Lyons, Jesse, Douglas K. Brubaker, Phaedra C. Ghazi, et al.. (2018). Integrated in vivo multiomics analysis identifies p21-activated kinase signaling as a driver of colitis. Science Signaling. 11(519). 24 indexed citations

Lyons, Jesse, Phaedra C. Ghazi, Alina Starchenko, et al.. (2018). The colonic epithelium plays an active role in promoting colitis by shaping the tissue cytokine profile. PLoS Biology. 16(3). e2002417–e2002417. 34 indexed citations

Hardie, Joseph, Ying Jiang, Phaedra C. Ghazi, et al.. (2016). Simultaneous cytosolic delivery of a chemotherapeutic and siRNA using nanoparticle-stabilized nanocapsules. Nanotechnology. 27(37). 374001–374001. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact